Kang, D.-H., Kwon, S.-H., Sim, W.-Y., & Lew, B.-L
Where each drug stands right now If you want the market snapshot in one section, it is this: Semaglutide the established modern GLP-1 benchmark FDA approved broad real-world use still highly effective no longer the ceiling Tirzepatide the current approved leader in weight-loss magnitude FDA approved directly beat semaglutide in SURMOUNT-5 still the most important approved comparator in the field Retatrutide still investigational strongest weight-loss headline of the three mechanistically the most ambitious because of added glucagon activity likely to be one of the most important obesity-market catalysts if late-stage development continues to hold up So which one is best
Avoiding contamination Never touch the needle with anything
Transl Med
Seek urgent medical attention if you develop severe, persistent abdominal pain that radiates to your back, especially if accompanied by nausea and vomiting
To hit its guidance Hims must keep driving compounded semaglutide, since it is resonable to expect the core growth to remain at a modest level
